{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T13:47:39Z","timestamp":1744379259384},"reference-count":21,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.3892\/ol.2012.971","type":"journal-article","created":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T06:04:31Z","timestamp":1350367471000},"page":"35-38","source":"Crossref","is-referenced-by-count":3,"title":["Pegylated liposomal doxorubicin for platinum-resistant or refractory M\u00fcllerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of Fallopian tube and peritoneal carcinoma): A single-institutional experience"],"prefix":"10.3892","volume":"5","author":[{"given":"TAKESHI","family":"FUKUDA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOSHIYUKI","family":"SUMI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASATOMO","family":"TERAMAE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUSUKE","family":"NAKANO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASANARI","family":"MORISHITA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HIROYUKI","family":"TERADA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HIROYUKI","family":"YOSHIDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YOSHINARI","family":"MATSUMOTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOMOYO","family":"YASUI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"OSAMU","family":"ISHIKO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2012,10,16]]},"reference":[{"key":"key20180108093000_b1-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"key20180108093000_b2-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/S0002-9378(12)91832-3","article-title":"Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial","volume":"170","author":"Seewaldt","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"key20180108093000_b3-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/0277-5379(91)90011-2","article-title":"Long-term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for Ovarian Cancer","volume":"27","author":"Neijt","year":"1991","journal-title":"Eur J Cancer"},{"key":"key20180108093000_b4-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1743-7563.2009.01263.x","article-title":"Recurrent ovarian cancer: Treat ment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre Experience","volume":"6","author":"Dear","year":"2010","journal-title":"Asia Pac J Clin Oncol"},{"key":"key20180108093000_b5-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/1097-0142(20010101)91:1<90::AID-CNCR12>3.0.CO;2-A","article-title":"Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome","volume":"91","author":"Safra","year":"2001","journal-title":"Cancer"},{"key":"key20180108093000_b6-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.1991.9.9.1668","article-title":"Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta Analysis Project","volume":"9","year":"1991","journal-title":"J Clin Oncol"},{"key":"key20180108093000_b7-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.1995.13.3.726","article-title":"Impact of doxorubicin on survival in advanced ovarian cancer","volume":"13","author":"A\u2019Hern","year":"1995","journal-title":"J Clin Oncol"},{"key":"key20180108093000_b8-ol-05-01-0035","first-page":"954","article-title":"Meta-analysis of cisplatin, doxorubicin and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma","volume":"80","author":"Fanning","year":"1992","journal-title":"Obstet Gynecol"},{"key":"key20180108093000_b9-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"key20180108093000_b10-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-199700544-00005","article-title":"Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumors","volume":"54","author":"Gabizon","year":"1997","journal-title":"Drugs"},{"key":"key20180108093000_b11-ol-05-01-0035","first-page":"1414","article-title":"Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma","volume":"97","author":"Collins","year":"2005","journal-title":"J Natl Med Assoc"},{"key":"key20180108093000_b12-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"key20180108093000_b13-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/TCRM.S3348","article-title":"Pegylated liposomal doxorubicin in the management of ovarian cancer","volume":"6","author":"Ferrandina","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"key20180108093000_b14-ol-05-01-0035","first-page":"1185","article-title":"Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial","volume":"5","author":"Gladieff","year":"2011","journal-title":"Ann Oncol"},{"key":"key20180108093000_b15-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1093\/annonc\/mdr001","article-title":"Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCGI) CALYPSO sub-study","volume":"22","author":"Kurtz","year":"2011","journal-title":"Ann Oncol"},{"key":"key20180108093000_b16-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","article-title":"Phase II study of stealth liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer","volume":"18","author":"Gordon","year":"2000","journal-title":"J Clin Oncol"},{"issue":"Suppl 9","key":"key20180108093000_b17-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0959-8049(01)00329-X","article-title":"Caelyx: phase II studies in ovarian cancer","volume":"37","author":"Johnston","year":"2001","journal-title":"Eur J Cancer"},{"key":"key20180108093000_b18-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase II study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"key20180108093000_b19-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/jjco\/hyn101","article-title":"Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with M\u00fcllerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: A phase II study of the Japanese Gynecologic Oncology Group","volume":"38","author":"Katsumata","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"key20180108093000_b20-ol-05-01-0035","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J Clin Oncol"},{"key":"key20180108093000_b21-ol-05-01-0035","first-page":"380","article-title":"Interim analysis of a phase III randomized trial of doxil\/caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer","volume":"9","author":"Gordon","year":"2000","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2012.971\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T10:51:57Z","timestamp":1515408717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2012.971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,16]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,10,16]]},"published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.3892\/ol.2012.971"],"URL":"https:\/\/doi.org\/10.3892\/ol.2012.971","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,16]]}}}